ANEUVO's Innovative Home Study Enhances ExaStim® Accessibility
ANEUVO Introduces ASPIRE™ Home Study for ExaStim® Device
ANEUVO, a pioneering force in non-invasive therapy development, has made a significant announcement regarding the ASPIRE™ Home Study. This initiative marks an essential milestone in the clinical research of their flagship neuromodulation device, the ExaStim® Stimulation System. The primary objective of this study is to tackle an urgent challenge faced by individuals living with chronic spinal cord injuries (SCI): accessing clinic-level therapies from the comfort of their homes.
Study Overview
The ASPIRE™ Home Study is set to focus on enhancing upper limb motor function and aims to enroll approximately 30 to 35 participants who previously took part in the initial ASPIRE trial. This research will be framed as a single-arm, prospective, observational study, anticipated to span six months from the enrollment phase to completion. Throughout the study, all participants will engage in ExaStim therapy.
Therapy Accessibility
Participants will have flexibility in how they utilize the device, with no limits on the number of stimulation sessions they can undertake. However, to ensure accurate data collection, the study imposes specific minimum and maximum stimulation time requirements they should adhere to each week. This approach aims to yield valuable insights regarding the device's application in everyday settings outside controlled clinical environments.
Data Collection and Facilities Involved
The study will harness the expertise of clinical teams from various prestigious institutions. These include Marquette University College of Health Sciences, Spaulding Rehabilitation Hospital, Craig Hospital, Kennedy Krieger Institute, and TryAbility Neurorecovery Center. They will collectively oversee data collection and analysis, contributing their wealth of knowledge to advance the study's goals.
Expert Insight
Dr. Randy Trumbower, Principal Investigator for the study at Spaulding Rehabilitation Hospital, expressed the significance of testing the ExaStim device in a home setting. He stated, "Understanding how daily engagement with this technology can empower individuals with chronic spinal cord injuries is an important advancement. This phase of research is set to evaluate the device's real-world impact, which could lead to newfound independence for these patients."
Building on Previous Research
The ASPIRE™ trial, the foundational study for this new research phase, previously evaluated the safety and efficacy of ExaStim® conducted across 14 sites throughout the United States. With over 120 participants having completed that pivotal study, ANEUVO gathered essential data that serves as a launching point for the ASPIRE Home Study.
Enhancing Lives through Home Therapy
By allowing participants to engage with ExaStim therapy in their own homes, this study not only aims to enhance the comfort and convenience for users but also to gauge the potential for increased adherence to the therapeutic regimen. Improving adherence means better outcomes, ultimately allowing individuals to integrate this innovative device into their everyday lives.
Commitment to Healthcare Innovation
ANEUVO remains dedicated to developing transformative bioelectronic medicine. Their mission is to empower patients facing chronic conditions by restoring functional independence and improving overall quality of life. By leveraging advanced biotechnological innovations and deep expertise, ANEUVO is diligently addressing critical healthcare challenges to provide solutions that may significantly enhance the lives of underserved populations.
Stay Informed
If you wish to learn more about ANEUVO and the groundbreaking ASPIRE Home Study, please visit www.aneuvo.com.
Frequently Asked Questions
What is the focus of the ASPIRE™ Home Study?
The ASPIRE™ Home Study focuses on evaluating the upper limb motor function improvement in individuals with spinal cord injuries using the ExaStim® device.
How many participants are expected in the study?
Approximately 30 to 35 participants who previously engaged in the initial ASPIRE trial will participate in the study.
What institutions are involved in data collection?
Data will be collected by clinical teams from several organizations, including Marquette University, Spaulding Rehabilitation Hospital, and Craig Hospital.
What is the anticipated duration of the study?
The ASPIRE™ Home Study is expected to last six months from enrollment to completion.
How does home therapy benefit participants?
Home therapy increases accessibility and potentially enhances adherence to treatment, leading to improved outcomes for individuals using ExaStim®.
About The Author
Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
